These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 1432619)
21. Concentration-dependent disposition of glucuronide metabolite of valproate. Yu HY; Shen YZ J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. Bialer M J Control Release; 1999 Nov; 62(1-2):187-92. PubMed ID: 10518650 [TBL] [Abstract][Full Text] [Related]
23. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269 [TBL] [Abstract][Full Text] [Related]
24. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. McCabe PH; Michel NC; McNew CD; Lehman EB Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766 [TBL] [Abstract][Full Text] [Related]
25. Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics. Herranz JL; Arteaga R; Adín J; Armijo JA Eur J Clin Pharmacol; 2006 Oct; 62(10):805-15. PubMed ID: 16896786 [TBL] [Abstract][Full Text] [Related]
26. Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate. Hokama N; Hobara N; Kameya H; Ohshiro S; Hobara N; Sakanashi M J Pharm Pharmacol; 2007 Mar; 59(3):383-6. PubMed ID: 17331341 [TBL] [Abstract][Full Text] [Related]
27. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study. Nagai G; Ono S; Yasui-Furukori N; Nakamura A; Mihara K; Kondo T Ther Drug Monit; 2009 Oct; 31(5):592-6. PubMed ID: 19704403 [TBL] [Abstract][Full Text] [Related]
28. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid. Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat. Singh K; Orr JM; Abbott FS Drug Metab Dispos; 1988; 16(6):848-52. PubMed ID: 2907464 [TBL] [Abstract][Full Text] [Related]
30. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid. Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Bialer M; Haj-Yehia A; Barzaghi N; Pisani F; Perucca E Eur J Clin Pharmacol; 1990; 38(3):289-91. PubMed ID: 2111246 [TBL] [Abstract][Full Text] [Related]
32. An improved gas chromatographic determination of valproic acid and valpromide in plasma. Pokrajac M; Miljković B; Spiridonović D; Varagić VM Pharm Acta Helv; 1992; 67(8):237-40. PubMed ID: 1409759 [TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Löscher W; Nau H; Marescaux C; Vergnes M Eur J Pharmacol; 1984 Mar; 99(2-3):211-8. PubMed ID: 6428923 [TBL] [Abstract][Full Text] [Related]
34. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Booth CL; Pollack GM; Brouwer KL Hepatology; 1996 Apr; 23(4):771-80. PubMed ID: 8666331 [TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate. Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406 [TBL] [Abstract][Full Text] [Related]
36. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity. Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397 [TBL] [Abstract][Full Text] [Related]
37. In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits. Nakashima M; Takeuchi N; Hamada M; Matsuyama K; Ichikawa M; Goto S Biol Pharm Bull; 1994 Dec; 17(12):1630-4. PubMed ID: 7735208 [TBL] [Abstract][Full Text] [Related]
38. [Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. Chen ZJ; Wang XD; Zhou LM; Fang ZY; Wang HS; Li JL; Zhou JQ; Huang HB; Huang M Yao Xue Xue Bao; 2014 Apr; 49(4):530-4. PubMed ID: 24974473 [TBL] [Abstract][Full Text] [Related]
39. Treatment of childhood epilepsy with rectal valproate: case reports and pharmacokinetic study. Kanazawa O; Sengoku A; Kawai I Brain Dev; 1987; 9(6):615-20. PubMed ID: 3128135 [TBL] [Abstract][Full Text] [Related]
40. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]